Evidence map›Paper›PMID 29045893›Full record

ArticleImmunity2017

HIV-1 Latency by Transition.

Boris Julg, Dan H Barouch

Abstract readComment
PubMed Publisher
In one paragraph

Article in Immunity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Boris JulgCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139, USA.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139, USA. Electronic address: dbarouch@bidmc.harvard.edu.

Funding

Optimizing HIV-specific T-cell responses by therapeutic vaccinationR01AI138790 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI JUELG, BORIS DOMINIK · 2019 to 2024
$2.8M
Vaccine induced T-cell protection against SIV infectionK08AI106408 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI JUELG, BORIS DOMINIK · 2013 to 2017
$938k
NIAID NIH HHS K08 AI106408NIAID NIH HHS R01 AI138790
6 · The paper itself

Abstract

The latent HIV-1 reservoir represents the major barrier for the development of an HIV-1 cure. In this issue of Immunity, Shan et al. (2017) highlight that effector-to-memory transitioning (EMT) CD4

Indexed as

HIV-1HIV InfectionsCD4-Positive T-LymphocytesHumansVirus Latency

Identifiers

PMID29045893

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.